Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 10 versus DEXTROSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 10 versus DEXTROSTAT.
ADDERALL XR 10 vs DEXTROSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
10 mg orally once daily in the morning; maximum dose 40 mg/day.
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
None Documented
None Documented
Dexamphetamine: 10-13 hours in adults (children: 6-8 hours); levoamphetamine: 13-16 hours; clinically, steady-state achieved in approximately 3 days, with twice-daily dosing maintaining therapeutic levels
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
Renal (approximately 30-40% as unchanged amphetamine, remainder as metabolites, including deaminated and oxidized products; urinary pH-dependent elimination: acidic pH increases renal clearance, alkaline pH decreases renal clearance; negligible biliary/fecal elimination)
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category C
CNS Stimulant
CNS Stimulant